Skip to main content

Vascular α1D-adrenoceptors are overexpressed in aorta of the aryl hydrocarbon receptor null mouse: role of increased angiotensin II

Buy Article:

$51.00 plus tax (Refund Policy)



1 The hypothesis that α1D-adrenoceptors may mediate the pro-hypertensive actions of angiotensin II (Ang II) was tested in isolated aorta (α1D-adrenoceptor bearing tissue) of the aryl hydrocarbon receptor null mouse (AhR−/−), which shows increased levels of Ang II, cardiac hypertrophy and hypertension.

2 The effect of captopril (an angiotensin converting enzyme inhibitor) on both blood pressure and aortic α1D-adrenoceptor expression and function in mice were determined.

3 Basal blood pressure was higher in AhR−/− mice, while captopril therapy decreased it to wild-type (WT) values.

4 Aortas of adult WT and AhR−/− mice were stimulated by phenylephrine or noradrenaline to induce contraction; the maximal effect was higher in AhR−/− mice, without a significant change in pEC50.

5 PA2 values for the selective α1D-adrenoceptor antagonist BMY 7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazynil]ethyl]-8-azaspiro [4.5]decane-7,9-dione) were 9.19 and 8.94 for WT and AhR−/−, respectively; while Schild slopes were not different from 1.

6 PCR experiments showed c. 77% increase in AhR−/−α1D-adrenoceptors cDNA compared with WT mice; while western blot analysis demonstrated c. 88% increase in α1D-adrenoceptor protein in AhR−/− mice.

7 Captopril therapy decreased α1D-adrenoceptor-induced contraction and protein in AhR−/− mice to WT levels.

8 These data support the hypothesis that under conditions where Ang II is elevated, vascular α1D-adrenoceptors are increased, and further suggest that both Ang II and vascular α1D-adrenoceptors could be related in the onset of hypertension.

Keywords: angiotensin II; aryl hydrocarbon receptor null mouse; captopril; hypertension; α1D-adrenoceptors

Document Type: Research Article


Affiliations: 1: Unidad de Biomedicina, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, México 2: Departamento de Farmacobiología, Sede Sur, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, México D.F., México 3: Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA 4: Sección Externa de Toxicología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, México D.F., México

Publication date: April 1, 2008

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more